Captor Therapeutics SA has offered an update on its lead programs CT-01, CT-02 and CT-05. In the CT-01 program, CPT-6281 is currently undergoing IND/CTA-enabling studies with the first clinical trial expected to start at the end of the year. The first indication will be in hepatocellular carcinoma (HCC).

Investigators at Edinburgh University have discovered that the stem cell transcription factor SALL4 can recognize and bind to short AT-rich motifs across the genome and downregulate genes that are present in AT rich regions.